ChemoCentryx to Present at Three Upcoming Investor Conferences
September 05 2017 - 8:30AM
ChemoCentryx, Inc., (Nasdaq:CCXI), a biopharmaceutical company
developing new medications targeted at inflammatory and autoimmune
diseases and cancer, today announced that Thomas J. Schall, Ph.D.,
President and Chief Executive Officer, will present at three
upcoming investor conferences in September:
- Rodman & Renshaw 19th Annual Global Investment
ConferenceMonday, September 11, 2017 at 3:50 p.m. Eastern
TimeLotte New York Palace Hotel, New York, NY
- Ladenburg Thalmann 2017 Healthcare
ConferenceTuesday, September 26, 2017 at 10:30 a.m.
Eastern TimeSofitel Hotel, New York, NY
- Cantor Fitzgerald 2017 Global Healthcare
ConferenceWednesday, September 27, 2017 at 2:15 p.m.
Eastern TimeInterContinental New York Barclay Hotel, New York,
NY
Live audio webcasts of the presentations can be accessed through
the Investors section of the Company's website at
www.ChemoCentryx.com. Replays of the webcasts will be available on
the Company's website for two weeks following each live
presentation.
About ChemoCentryx
ChemoCentryx is a biopharmaceutical company developing new
medications targeted at inflammatory and autoimmune diseases and
cancer. ChemoCentryx targets the chemokine and chemoattractant
systems to discover, develop and commercialize orally-administered
therapies. ChemoCentryx is currently focusing on its late stage
drug candidates for patients with rare kidney diseases, avacopan
(CCX168) and CCX140.
Avacopan is an orally-administered small molecule that is a
selective inhibitor of the complement C5a receptor, or C5aR.
Avacopan is in Phase III development for the treatment of
anti-neutrophil cytoplasmic auto-antibody-associated vasculitis
(AAV). In clinical studies to date, avacopan was shown to be safe,
well tolerated and provided effective control of the disease while
allowing elimination of high-dose steroids, part of the current
standard of care. Avacopan is also being developed in patients with
C3 glomerulopathy (C3G) and atypical hemolytic uremic syndrome
(aHUS). The U.S. Food and Drug Administration has granted avacopan
orphan-drug designation for AAV, C3G and aHUS. The European
Medicines Agency (EMA) has granted orphan medicinal product
designation for avacopan for the treatment of two forms of AAV:
microscopic polyangiitis and granulomatosis with polyangiitis
(formerly known as Wegener's granulomatosis), as well as for C3G.
Avacopan was also granted access to the EMA's PRIority MEdicines
(PRIME) initiative, which supports accelerated assessment of
investigational therapies addressing unmet medical need.
The Company's other late stage drug candidate is CCX140, an
inhibitor of the chemokine receptor known as CCR2, which is
currently being developed for patients with focal segmental
glomerulosclerosis (FSGS), a debilitating kidney disease.
ChemoCentryx's Kidney Health Alliance with Vifor Pharma provides
Vifor Pharma with exclusive rights to commercialize avacopan and
CCX140 in markets outside of the U.S. and China.
ChemoCentryx also has early stage drug candidates that target
chemoattractant receptors in other Inflammatory and autoimmune
diseases and in cancer.
Contacts:
Susan M. Kanaya
Executive Vice President, Finance and Chief Financial and Administrative Officer
investor@chemocentryx.com
Media:
Stephanie Tomei
408.234.1279
tomei.stephanie@gmail.com
Investors:
Burns McClellan, Inc.
Steve Klass
212.213.0006
sklass@burnsmc.com
ChemoCentryx (NASDAQ:CCXI)
Historical Stock Chart
From Apr 2024 to May 2024
ChemoCentryx (NASDAQ:CCXI)
Historical Stock Chart
From May 2023 to May 2024